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Abstract 
The mechanism of progression from ductal carcinoma in situ (DCIS) to invasive ductal car-
cinoma (IDC) remains largely unknown. We compared gene expression in tumors with 
simultaneous DCIS and IDC to decipher how diverse proteins participate in the local invasive 
process. 
Twenty frozen tumor specimens with concurrent, but separated, DCIS and IDC were mi-
crodissected and evaluated. Total RNA was extracted and microarray analysis was performed 
using Affymetrix GeneChip® Human Gene 1.0 ST Arrays. Microarray data were validated by 
quantitative real time reverse transcription-PCR (qRT-PCR) and immunohistochemistry. 
Controls included seven pure in situ carcinomas, eight fragments from normal breast tissue, 
and a series of mouse breast carcinomas (MMTV-PyMT).  
Fifty-six genes were differentially expressed between DCIS and IDC samples. The genes 
upregulated in IDC samples, and probably associated with invasion, were related to the ep-
ithelial-mesenchymal transition (ASPN, THBS2, FN1, SPARC, and COL11A1), cellular adhesion 
(GJB2), cell motility and progression (PLAUR, PLAU, BGN, ADAMTS16, and ENPP2), extracellular 
matrix degradation (MMP11, MMP13, and MMP14), and growth/proliferation (ST6GAL2). 
qRT-PCR confirmed the expression patterns of ASPN, GJB2, ENPP2, ST6GAL2, and TMBS10. 
Expression of the ASPN and GJB2 gene products was detected by immunohistochemistry in 
invasive carcinoma foci. The association of GJB2 protein expression with invasion was con-
firmed by qRT-PCR in mouse tumors (P < 0.05).  
Conclusions: The upregulation of ASPN and GJB2 may play important roles in local invasion 
of breast ductal carcinomas. 
Key words: breast cancer, in situ ductal carcinoma, invasive ductal carcinoma, epitheli-
al-mesenchymal transition, ASPN, GJB2. 
INTRODUCTION 
Invasive ductal carcinoma (IDC) of the breast is a 
heterogeneous disease with a variety of histological 
subtypes. Tumor cell invasion is a complex process 
and the mechanisms controlling the transition from 
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ductal carcinomas in situ (DCIS) to IDC still remain 
unclear, despite research in recent years. Initial 
pathological studies suggest that IDC is preceded by 
DCIS, “atypical ductal hyperplasia”, and “usual duc-
tal hyperplasia” (1). The current hypothesis is that 
genetic changes modulating invasiveness are present 
in cells even before they acquire DCIS morphology 
(2-4). Furthermore, not all in situ lesions become in-
vasive, some IDCs are not associated with DCIS and, 
thus, the mechanisms of invasion in breast carcinomas 
remain unclear.  
Gene expression profiling using microarray 
technology has allowed for major advances in the 
classification of breast cancers. Although DCIS ac-
counts for 15-40% of all diagnosed breast cancers (5), 
transcriptome studies of DCIS have proven difficult. 
Only a few studies with small sample numbers have 
compared the gene expression patterns of DCIS with 
those of IDC (2, 3, 6-10). Furthermore, only a few of 
the studies included breast carcinomas in which sim-
ultaneous DCIS and IDC components were separated 
and compared (2, 3, 7, 8). Although few coincidences 
of specific genes occurred in these studies, it is sug-
gested that upregulation of IDC genes is associated 
with epithelial-mesenchymal transition (EMT), cell 
motility, extracellular matrix degradation, and 
growth/proliferation. Since these studies are incom-
plete, further work in this area is needed to under-
stand the molecular mechanisms of cell invasion in 
this form of neoplasia.  
In the current study, we identified genes that 
were differentially expressed in IDC and DCIS by 
analyzing tumors containing simultaneously sepa-
rated foci with both components. Our results demon-
strate that the ASPN and GJB2 genes would have an 
important role in the mechanism of progression from 
DCIS to local invasion in breast carcinomas. 
MATERIALS AND METHODS 
Patients and tumor samples  
This study was conducted according to the Dec-
laration of Helsinki principles with approval by the 
ethics committee of the Institut de Recerca, Hospital 
de la Santa Creu i Sant Pau, Autonomous University, 
Barcelona, Spain. Twenty human breast carcinomas 
containing DCIS and IDC lesions (matched samples) 
were collected prospectively at the Department of 
Pathology at Hospital de la Santa Creu i Sant Pau 
between 2006 and 2010. In addition, seven pure DCIS 
samples and eight normal breast tissue samples were 
retrospectively selected as controls. Immediately after 
surgery, a portion of each tumor was rapidly embed-
ded in OCT (Tissue-Tek, Sakura, Europe, Alphen aan 
den Rijn, The Netherlands) and frozen using a histo-
bath (Thermo Shandon, Pittsburgh, PA, USA). The 
remaining tumor tissues were fixed in buffered 10% 
formalin and fixed in paraffin. H&E staining was used 
for pathological diagnosis of sections and tumor clas-
sification and grading was performed using standard 
methods. Clinical-pathological data are summarized 
in Table 1. 
 
Table 1. Main clinicopathological characteristics of patients 
and tumors.  
Age ≥55 11 (55%) 
 <55 9 (45%) 
Tumor size (cm) <2 4 (20%) 
 2-5 14 (70%) 
 >5 2 (10%) 
Lymph node metastasis Positive 8 (40%) 
 Negative 12 (60%) 
Histological grade  I 3 (15%) 
 II 8 (40%) 
 III 9 (45%) 
Mitosis (sq mm/10) <7 9 (45%) 
 7-13 5 (25%) 
 >13 6 (30%) 
Nuclear atypia 1 1 (5%) 
 2 5 (25%) 
 3 14 (70%) 
Tumor necrosis Positive 8 (40%) 
 Negative 12(60%) 
Lymphatic invasion Positive 5 (25%) 
 Negative 15 (75%) 
DCIS >10% 15 (75%) 
 <10% 5 (25%) 
Estrogen receptors Positive 17 (85%) 
 Negative 3 (15%) 
Progesterone receptors Positive 9 (45%) 
 Negative 11 (55%) 
Her-2/neu Positive  13 (65%) 
 Negative 7 (35%) 
Immunohistochemical subtype HR+/Her 2 -* 10 (50%) 
 HR+/Her2+ 7 (35%) 
 HR-/Her2+ 2 (10%) 
 HR-/Her2- 1 (5%) 
* HR= Hormone receptors (either estrogen and or progesterone 
receptors); Her= HER2/neu; +=positive;-=negative 
 
 
RNA isolation 
Dissection of independent DCIS and IDC foci 
was done after examination of an H&E stained section 
of the OCT-embedded frozen tumor. Although DCIS 
and IDC were independently isolated, associated 
stroma would be mixed with each tumor component. 
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This limitation was lately overcome by the immuno-
histochemical detection and visualization of the can-
didate-gene products. 
Total RNA was isolated from selected areas of 
frozen tissue using TRIzol Reagent (Invitrogen, 
Carlsbad, CA, USA) and purified using an RNeasy 
Mini Kit (QIAGEN, Hilden, Germany) according to 
manufacturers’ instructions. RNA was resuspended 
in 14 µl RNase-free H2O and stored at -80°C. RNA 
concentrations and quality were determined using a 
NanoDrop apparatus (Thermo Fisher Scientific, Wil-
mington, DE, USA) and RNA integrity numbers (RIN) 
were analyzed using a RNA 6000 Nano LabChip Kit 
(Agilent Technologies, Boeblingen, Germany) with a 
Agilent 2100 Bioanalyzer according to the manufac-
turer’s instructions. 
Microarray analysis 
Microarray analysis was performed using 
Affymetrix GeneChip® Human Gene 1.0 ST Arrays 
(Affymetrix, Santa Clara, CA, USA) that consists of 
approximately 764,885 probe sets with a resolution 
number of 26 probes per gene, covering over 28,869 
genes. The entire process was performed following 
the Affymetrix instructions. Briefly, double-stranded 
cDNA was synthesized by a chimerical oligonucleo-
tide with oligo-dT and T7 RNA polymerase. The am-
plification and labeling processes were monitored 
using a GeneChip® Eukaryotic Poly-A RNA Control 
Kit (Affymetrix) with exogenous positive controls that 
were spiked into the total RNA before cDNA synthe-
sis. In all cases, 25 µg of each biotinylated cRNA 
preparation was fragmented and placed in hybridiza-
tion cocktail containing biotinylated hybridization 
controls (GeneChip® Expression Hybridization Con-
trols, Affymetrix). Samples were hybridized onto a 
GeneChip® Human Gene 1.0 ST Array at 45°C with 
60 rpm for 17 hours in a Hybridization Oven 640 
(Affymetrix). Microarray scanned images were ob-
tained with a GeneChip Scanner 3000 7G (Affymetrix) 
using the default settings. Images were visually in-
spected to eliminate hybridization artifacts.  
Images were analyzed with R/Bioconductor 
software using the Oligo (11) and LIMMA packages 
(12). Adjustment for multiple tests was performed 
using Benjamini-Hochberg False Discovery Rate cor-
rection (13). Further information on the genes was 
obtained from GeneCards (http://www.genecards. 
org) and NCBI databases (http://www.ncbi.nlm. 
nih.gov). Functional annotation was performed by 
uploading the resulting gene list onto DAVID (Data-
base for Annotation, Visualization and Integrated 
Discovery, http://david.abcc.ncifcrf.gov) using the 
GOTERM database. Genes were mapped to 
KEGG-pathways and scored according to P values 
(EASE Score, modified Fisher’s exact test) and cor-
rected for multiple testing according to the Benja-
mini-Hochberg False Discovery Rate correction.  
Hierarchical clustering 
Unsupervised clustering analysis was performed 
using an average-linkage hierarchical clustering of a 
centered correlation similarity matrix of DCIS and 
IDC samples with 253 genes from the intrinsic gene 
list previously described (14). Genes were filtered and 
visualized, using GeneCluster 3.0 and TreeView 
software, respectively.  
Reverse transcription and qRT-PCR 
Reverse transcription was performed using 1 μg 
of total RNA extracted from each of 20 matched 
DCIS/IDC samples, 7 pure DCIS, and 8 normal breast 
tissue samples using the High-Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Foster 
City, CA, USA). To analyze gene expression patterns, 
qRT-PCR was performed using specific TaqMan 
probes (Applied Biosystems) for ASPN 
(Hs00214385_m1), TMSB10 (Hs00363670_m1), KRT5 
(Hs00361185_m1), GJB2 (Hs00955889_m1), ENPP2 
(Hs00196470_m1), and ST6GAL2 (Hs00383541_m1). 
qRT-PCR was performed according to the manufac-
turer’s instructions using a 7500 Real Time PCR Sys-
tem (Applied Biosystems). Expression levels were 
measured in triplicate from each cDNA dilution. Rel-
ative gene expression was performed according to the 
comparative Ct (ΔΔCt) method using mitochondrial 
ribosome protein L19 (MRPL19) as an endogenous 
control. 
Immunohistochemistry (IHC) 
Tissue microarrays (TMAs) were prepared from 
formalin-fixed paraffin-embedded tissues obtained 
from three representative areas of each tumor. Tissue 
cores with 1 mm diameters were precisely arrayed in 
a paraffin block using a tissue microarray workstation 
(Beecher Instruments, Sun Prairie, WI, USA). For each 
TMA, H&E-stained slides were prepared to confirm 
the presence of the original selected tumor areas. Se-
rial, 5-m thick sections were stained using the EnVi-
sion method (DAKO, Glostrup, Denmark). Details of 
antibody and immunostaining conditions are sum-
marized in Table 2. Tumors were scored according to 
the intensity of cytoplasmic or nuclear staining as 
positive or negative (no staining or questionable sig-
nal intensities). All immunohistochemical results 
were evaluated separately by two pathologists (GP 
and EL) and discordant results were reviewed to 
achieve agreement. 
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Table 2. Primary Antibodies and other conditions for immunohistochemical analysis 
Antibody Clone Dilution Supplier Pretreatment 
ER SP11 1:1* Dako PT link pH 9. 
PR PgR636 1:1* Dako PT link pH 9. 
Ki-67 MIB-1 1:1* Dako PT link pH 6. 
Cam 5.2  Cam 5.2 1:2* Dako PT link pH 6. 
CK 5/6  D5/16 B4 1:1* Dako PT link pH 9. 
Vimentin V9, Dako 1:1* Dako PT link pH 9. 
Asporin (ASPN) Polyclonal 1:200 Covalab PT link pH 9. 
 Connexin 26 (GJB2) Polyclonal 1:10 Antibodies-online.com PT link pH 6. 
ST6GAL2 Polyclonal 1:20 Sigma PT link pH 6. 
Herceptest Polyclonal 1:1* Dako HerceptestTM for Automated Link Platforms 
* Pre-diluted Ab 
 
Mouse tumor samples 
Animal protocols used in this study were ap-
proved by the Institutional Animal Care and Use 
Committee of the Institut de Recerca, Hospital de la 
Santa Creu i Sant Pau. Mouse tumor samples were 
kindly provided by Dr. Blanco-Vaca (Sant Pau Re-
search Institute, Barcelona, Spain). MMTVPyMTTg 
mice express high levels of the transforming oncogene 
polyoma virus middle T antigen (PyMT) under the 
control of the mouse mammary tumor virus long 
terminal repeat promoter, which specifically directs 
expression to the mammary epithelium. Mice spon-
taneously develop widespread multifocal adeno-
mas/DCIS at 8 weeks and invasive/metastatic carci-
nomas at 13 weeks. The similarities between the 
PyMT model and human breast cancer have been 
validated by histological studies demonstrating a 
striking similarity between PyMT carcinogenesis and 
various stages of human ductal carcinoma progres-
sion (15). Genotyping was performed as indicated at 
Jackson Laboratories, Bar Harbor, ME, USA. Gene 
expression of mouse tissues was performed as de-
scribed above for human tissues.  
Statistical analyses  
Differences among groups were analyzed for 
statistical significance with non-parametric 
Mann-Whitney U tests or by one-way analysis of 
variance (ANOVA) using SPSS Statistics 18 software 
(Chicago, IL, USA). In addition, when the variance 
was not homogeneous, we used the Kruskal-Wallis 
test. Results are expressed as means ± SE and differ-
ences were considered to be significant if P <0.05. 
RESULTS 
Tissue selection and clinical-pathological data 
Twenty breast cancer patients with tumors con-
taining simultaneous foci of DCIS and IDC were se-
lected for this study (Table 1). The median age of the 
patients was 60 years (range 36-78 years). The average 
tumor size was 2.3 cm (range 0.5-15 cm). Axillary 
lymph node metastases were detected in eight pa-
tients. The histological grades for IDCs were I in three 
tumors (15%), II in eight tumors (40%), and III in nine 
tumors (45%). Ten tumors were positive for hormone 
receptors (HRs), estrogen receptor (ER), and/or pro-
gesterone receptor (PR) and were negative for HER2 
(HR+/HER2-). Seven tumors were HR/HER2+, two 
tumors were HR-/HER2+, and one tumor was 
HR/HER2-. The median percentage for the Ki67 pro-
liferation index was 13% for IDC tumors (range 
5-80%) and atypical nuclei coincided with the invasive 
and in situ component. The DCIS fraction of tumors 
was greater than10% in 15 samples and comedo ne-
crosis was detected in five cases. HER2 was overex-
pressed in 11 DCIS samples. The median Ki67 index of 
DCIS was of 7% (range 3-40%) and only eight cases 
had a Ki67 greater than 20%. 
Comparative micro array analysis and hierar-
chical clustering of IDC-DCIS matched sam-
ples 
IDC and DCIS paired samples from the 20 tu-
mors were hybridized to the 10,945 spots on the 
GeneChip® Human Gene 1.0 ST Arrays and 1,158 
probe sets were found to be differentially regulated. 
After adjusting the P values, we found that 56 genes 
were differentially expressed in the IDC samples. 
Among these genes, 31 were upregulated in IDC 
samples compared to DCIS samples (Supplementary 
Material:  Table S1) and 25 were downregulated 
(Supplementary Material:  Table S2).  
Hierarchical clustering was performed using the 
Euclidian distance-generating function with probe 
sets differentially expressed in the microarray analy-
sis (14). Our results showed that tumor samples were 
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distributed into two well-differentiated clusters. The 
first cluster was composed of HR+/HER2- IDCs with 
the exception of one HER2+ tumor. The second cluster 
was composed mainly of DCIS samples, but also in-
cluded five HR-/HER2+ grade II IDC tumors and one 
HR-/HER”- sample.  
Interaction of tumor cells with stroma is re-
quired for tumor invasion 
Functional annotation of the differentially regu-
lated probe sets according to Gene Ontology revealed 
that several genes were upregulated in IDC compared 
with DCIS. These genes were involved in a) extracel-
lular matrix interactions and focal adhesions 
(COL11A1, COL10A1, FN1, COL12A1, MMP13, 
THBS2, SPARC, LRRC15, and ASPN), b) cell adhesion 
(GJB2), c) extracellular matrix remodelling and cell 
motility (PLAUR, PLAU, MMP11, and MMP14), d) 
calcium and metal binding and transport (GPC6, 
ADAMTS16, and BGN), most of which are members of 
the small proteoglycans family, e) genes encoding 
signal transducers (RGS16, ADORA3, PRR5L, and 
SPSB1), and f) enzymes involved in tumor growth 
(ENNP2 and ST6GAL2).  
In contrast, 25 genes were statistically downreg-
ulated in IDC compared to DCIS. Functions of these 
genes included a) metabolic and enzymatic functions 
(ACACB and PAMR1), b) tumor suppression 
(SERPINB5), c) cell cytoskeleton regulation (KRT5), 
and d) cell adhesion (LYVE1, TNXB, TNXA, and F8).  
Confirmation of differential gene expression 
between IDC and DCIS via qRT-PCR  
The expression of several genes that were shown 
to be upregulated in IDC compared to DCIS in the 
microarray analyses were further analyzed by 
qRT-PCR (Table 3). Our results confirmed the upreg-
ulation of ASPN, GJB2, ST6GAL2, ENPP2, and 
TMSB10 (P < 0.05), whereas KRT5 (P < 0.05) was 
downregulated in IDC compared to DCIS. When the 
analysis was performed in the group of HR+/HER2- 
tumors, the upregulation of ASPN, GJB2, and 
ST6GAL2 was confirmed in IDC (P < 0.05), but the 
differential expression of ENPP2 and TMSB10 was not 
significant. Therefore, ENPP2 and TMSB10 were ex-
cluded from further analyses. Invasive HR+/HER2+ 
carcinomas were differentiated from DCIS by elevat-
ed expression levels of SERPINB5. However, this gene 
was not differentially expressed in the overall analy-
sis. As seen in Figure 1, there were great differences in 
mRNA expression of asporin, GJB2, and ST6GAL2 
between the samples of DCIS associated with IDC and 
the samples of DCIS without invasion. Differential 
expression of these genes was not detected in the 
comparison between normal tissues and pure DCIS.  
Immunohistochemical expression of ASPN 
(asporin), GJB2 (connexin 26) and ST6GAL2  
To further validate our gene expression data, we 
performed an immunohistochemical study to deter-
mine the protein expression patterns of ASPN, GJB2, 
and ST6GAL2 on TMAs of the tumors. There was in-
tense asporin nuclear staining in approximately 50% 
of DCIS tumor cell nuclei (range 20-100; SD = 27.4), 
51.5% of IDC tumor nuclei (range 5-100; SD = 33), 
whereas only 4% of nuclei were stained in normal 
tissues (P < 0.001). Asporin staining was also present 
in nuclei of fibroblast, endothelial cells, and mature 
lymphocytes (Figure 1).  
Positive cytoplasmic staining of connexin 26 
(GJB2 gene product) was found in 18/20 IDC samples, 
16/20 DCIS samples, and only 2/20 normal breast 
tissue samples (P = 0.001). Connexin 26 was also pre-
sent in fibroblasts, endothelial cells, and the cyto-
plasm of mature histiocytes (Figure 1). However, 
ST6GAL2 protein immunostaining was heterogene-
ous and irregular in IDC and DCIS samples and neg-
ative in normal ductal breast epithelial cells. Positive 
controls included fibroblasts and endothelial cells.  
qRT-PCR analysis of gene expression in mouse 
tumors 
To analyze the expression of genes potentially 
associated with invasiveness, we utilized frozen ma-
terials from a spontaneous murine model of breast 
cancer (MMTV-PyMT). Gene expression was evalu-
ated by qRT-PCR. mRNA was obtained from tumors 
at 8 weeks (equivalent to the DCIS stage) and 13 
weeks (equivalent to the IDC stage) (15). The level of 
GJB2 was 134-fold higher in the DCIS samples and 
37-fold higher in IDC tumors (P < 0.05) with respect to 
normal mouse breast tissue. However, no significant 
differences were found between the DCIS and IDC 
samples. Furthermore, no differences in ASPN and 
ST6GAL2 levels were found (P = NS) (Figure 2). These 
analyses were repeated three times before validation. 
DISCUSSION 
The two main pathological hallmarks of neo-
plasia are local invasion and distant metastasis. The 
mechanisms of local invasion in breast DCIS and the 
progression to IDC are not well known. Thus, we 
compared gene expression patterns in simultaneous 
in situ and invasive areas of ductal carcinomas with 
the aim of elucidating the mechanism of breast carci-
noma invasiveness.  
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The classical multistep model of breast cancer 
progression hypothesized that IDC is preceded by 
DCIS, “atypical ductal hyperplasia”, and “usual duc-
tal hyperplasia” (16). Later, it was suggested that 
low-grade DCIS tends to progress to low grade IDC 
and, in parallel, high-grade DCIS tends to progress to 
high-grade IDC (17). Simultaneous assessments of 
multiple biological markers in DCIS and IDC, in-
cluding steroid receptors, HER-2, and cell cycle regu-
latory genes (p53, Ki-67, bcl-2, and p21) support this 
assessment (18). Nevertheless, these results did not 
improve the predictive power of standard pathologi-
cal parameters, nor did they explain the mechanism of 
invasiveness because the genetic changes that modu-
late invasiveness are likely already present in cells 
before the cells acquire the typical DCIS morphology 
(2-4). Recent chromosomal, genetic, and molecular 
studies support the theory of parallel disease for the 
progression of DCIS to IDC. However, it is likely that 
only a small subpopulation of highly tumorigenic and 
migrating cancer cells (0.1-3% of the total cancer cells) 
may be responsible for tumor growth, distant metas-
tases, treatment resistance, and recurrence (2-4).   
 
Figure 1. Expression of ASPN, GJB2, ENPP2, ST6GAL2, and TMSB10 genes. (A) Histograms showing differential gene expression be-
tween DCIS pure vs normal tissue, DCIS associate to IDC vs normal breast tissue, IDC vs normal tissue, DCIS associate to IDC vs DCIS 
pure samples and IDC vs DCIS pure samples. Gene expression levels of ASPN, GJB2, ENPP2, ST6GAL2 and TMSB10 were determined by 
qRT-PCR. The bar represents the mean ± S.E. of all samples by duplicate. Asterisks (*) indicates statistically significant differences (P < 
0.05). (B) Immunohistochemical images of asporin and GJB2 (connexin-26) expressions in normal tissue (black arrow), proliferative 
non-invasive (two black arrows) and invasive neoplasms (black star).  
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Figure 2. Microscopic images and qRT-PCR of mice tumors. (A) Microscopic images of typical breast tissue in MMTV-PyMT mice 
at ages of 0 weeks (considered as normal tissue), 8 weeks (equivalents to DCIS), and in 13 weeks (equivalent to IDC). Tumor proliferation 
overgrowth stroma with the time as the grade of nuclear atypia increases. Mitoses are clearly found in IDC (see arrow), H&E staining, x40 
magnification. (B) Histograms showing relative fold changes in gene expression by qRT-PCR of ASPN, GJB2, and ST6GAL2. Significative 
increased overexpression of GJB2 in DCIS and IDC with respect to normal tissue. Each bar represents the mean ± S.E. of all samples by 
duplicate. Asterisk (*) denote statistically significant differences (P < 0.05). 
 
 
 
Table 3. Validation of microarray-based gene expression results by qRT-PCR. 
 IDC vs. DCIS Total IDC vs. DCIS  
(n = 20) 
HR+/HER-2-  
(n = 10) 
HR+/HER-2+  
(n = 7) 
Gene Name, symbol Average FC*± SE Mean FC P Mean FC P Mean FC P 
Asporin , ASPN 3.336 ± 0.625 5.371 0.001 5.586 0.034 1.627 N.S. 
Maspin, SERPINB5 0.772 ± 0.114 0.949 N.S. 0.827 N.S. 6.732 <0.001 
Connexin 26, GJB2 1.1635 ± 0.181 5.276 0.001 3.088 0.007 1.651 N.S. 
Autotaxin,  ENPP2 1.019 ± 0.138 6.440 0.013 2.405 N.S. 2.548 N.S. 
ST6GAL2 1.493 ± 0.141 16.547 <0.001 13.026 0.002 2.952 N.S. 
Thymosin beta-10, TMSB10 1.075 ± 0.063 5.017 0.048 1.203 N.S. 1.797 N.S. 
Cytokeratin 5, KRT5 0.689 ± 0.106 0.385 0.004 0.492 N.S. 0.076 N.S. 
Notes: * Data from microarray analysis. Abbreviations: FC, fold-change; N.S., non-significant; HR, hormone receptors (including estrogen 
and progesterone receptors) 
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Breast tumor cell invasiveness is a complex pro-
cess that is related to genetic alterations of tumor cells, 
loss of myoepithelial cells, and a stromal facilitation of 
invasion that includes fibroblast activation, altered 
expression of growth and angiogenic factors, immu-
nological reactivity, and increased expression of 
chemokines and matrix metalloproteinases (MMPs) 
(4, 19-21). Many studies have analyzed the role of 
myoepithelial cells in blocking tumor cell invasive-
ness (3, 4, 7), which is not the subject of our study. 
Myoepithelial cells may compete with fibroblasts and 
with the inflammatory processes, which could facili-
tate invasion (4, 19, 21). 
Previous transcriptome studies underlines the 
cooperation of the stroma in breast carcinoma inva-
sion, which is associated with upregulation of EMT, 
cell motility, extracellular matrix (ECM) degradation, 
and cell proliferation, whereas genes related to cell 
adhesion and cytoskeletal intermediate filaments are 
generally downregulated (2, 4, 7, 8). Our results are in 
agreement with the upregulation of several genes 
related to the extracellular matrix (MMP11, MMP13, 
MMP14, SPARC, LLCR15, PLAU, and ASPN) and cell 
adhesion (GJB2) in breast carcinomas. We selected one 
gene from each category to further explore their func-
tions in these metabolic pathways.  
Several extracellular matrix proteins may favor 
invasiveness and their production may be stimulated 
by growth factors such as transforming growth factor 
beta (TGF-), which is controlled by several proteases, 
especially MMPs (20). The expression of TGF- family 
members was not significantly altered in our study 
despite their well-documented role in invasiveness (2, 
3, 8, 9) whereas we did observe upregulation of MMPs 
and asporin, which are involved in the TGF- regula-
tion. Asporin, encoded by ASPN, is a member of the 
leucine-rich repeat protein family that is associated 
with mesenchymal tissues (22). Asporin is produced 
by fibroblasts, inhibits TGF- effects, and has a para-
crine effect on prostate (23) and stomach (24) tumor 
cells. Although asporin was previously associated 
with invasive lobular carcinomas (25), we found that 
it has an important role in initial carcinogenesis 
(DCIS) and in invasiveness of IDC. In the present 
work, the level of asporin mRNA in IDC, as deter-
mined by qRT-PCR, was related to invasiveness and 
the expression of this protein was confirmed by im-
munohistochemistry in hormone-related cases of IDC 
and DCIS. In contrast, the activity of decorin, another 
member of the ASPN family of genes is controversial. 
Decorin expression has been correlated with poor 
prognosis in estrogen receptor-negative breast cancers 
(26). Other studies have indicated an inhibitory effect 
by decorin on both primary tumor growth and meta-
static spreading (27). 
The upregulation of genes related to cell adhe-
sion in carcinomas, such as GJB2, is unexpected be-
cause neoplasms are characterized by loss of cell co-
hesion. GJB2 encodes connexins 26 and 43, which 
participate in specialized structures on plasma mem-
branes by contacting adherent cells and forming 
cell-to-cell channels. In other tumors, such as colo-
rectal carcinomas, the prognostic significance of con-
nexin 26 is controversial (28, 29). In breast cancer cell 
cultures the downregulation of connexin 26 is associ-
ated with EMT inhibition (30). More recent studies of 
human breast carcinomas have shown an association 
of connexin 26 expression with invasion and lymph 
node metastases (31). Our transcriptome studies in-
dicated that GJB2 upregulation correlated with inva-
sion and increased GJB2 mRNA production was de-
tected by qRT-PCR. Connexin 26 was also identified 
by immunohistochemistry in tumor cells and in 
stroma. Furthermore, a statistical association of GJB2 
upregulation with DCIS was demonstrated in PyMT 
mouse samples, thus supporting its role in DCIS as-
sociated with IDC and pure IDC, but not in pure 
DCIS.  
Invasion is a multi-step process in which a mul-
tidirectional cross talk of tumor cells and stroma is 
modulated by paracrine signals coming from associ-
ated tumor-stroma and/or inflammatory processes. 
Our study confirmed that expression of ASPN and 
GJB2 occurs very early during carcinogenesis and 
may be related to the initiation of invasion and tumor 
dissemination. Further studies are required to confirm 
our data. These data would assist in the development 
of precise diagnostic markers of invasion and in the 
identification of new therapeutic targets.  
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